Search This Blog

Thursday, June 16, 2016

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease (NYSE:LLY)

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.